全文获取类型
收费全文 | 2088篇 |
免费 | 124篇 |
国内免费 | 29篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 144篇 |
妇产科学 | 95篇 |
基础医学 | 225篇 |
口腔科学 | 67篇 |
临床医学 | 196篇 |
内科学 | 520篇 |
皮肤病学 | 24篇 |
神经病学 | 157篇 |
特种医学 | 149篇 |
外科学 | 235篇 |
综合类 | 13篇 |
一般理论 | 1篇 |
预防医学 | 150篇 |
眼科学 | 23篇 |
药学 | 141篇 |
中国医学 | 3篇 |
肿瘤学 | 83篇 |
出版年
2022年 | 16篇 |
2021年 | 38篇 |
2020年 | 32篇 |
2019年 | 39篇 |
2018年 | 54篇 |
2017年 | 35篇 |
2016年 | 41篇 |
2015年 | 43篇 |
2014年 | 38篇 |
2013年 | 76篇 |
2012年 | 108篇 |
2011年 | 131篇 |
2010年 | 81篇 |
2009年 | 64篇 |
2008年 | 114篇 |
2007年 | 121篇 |
2006年 | 88篇 |
2005年 | 86篇 |
2004年 | 64篇 |
2003年 | 63篇 |
2002年 | 55篇 |
2001年 | 63篇 |
2000年 | 47篇 |
1999年 | 39篇 |
1998年 | 53篇 |
1997年 | 57篇 |
1996年 | 58篇 |
1995年 | 48篇 |
1994年 | 37篇 |
1993年 | 39篇 |
1992年 | 29篇 |
1991年 | 23篇 |
1990年 | 20篇 |
1989年 | 34篇 |
1988年 | 31篇 |
1987年 | 34篇 |
1986年 | 25篇 |
1985年 | 26篇 |
1984年 | 19篇 |
1983年 | 15篇 |
1982年 | 9篇 |
1980年 | 10篇 |
1979年 | 14篇 |
1978年 | 12篇 |
1977年 | 16篇 |
1976年 | 15篇 |
1975年 | 12篇 |
1974年 | 9篇 |
1970年 | 8篇 |
1966年 | 8篇 |
排序方式: 共有2241条查询结果,搜索用时 15 毫秒
71.
U. Martinowitz A. Shapiro D. V. Quon M. Escobar C. Kempton P. W. Collins P. Chowdary M. Makris P. M. Mannucci M. Morfini L. A. Valentino E. Gomperts M. Lee 《Haemophilia》2012,18(6):881-887
IB1001 trenacog alfa is an investigational recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with haemophilia B. To compare the pharmacokinetics (PK) of IB1001 with nonacog alfa in individuals with haemophilia B and to assess the relationship between sialylation and PK of IB1001 (NCT00768287). A randomized, double‐blind, non‐inferiority, cross‐over study conducted in participants aged ≥12 years weighing ≥40 kg, with severe or moderately severe haemophilia B (FIX activity ≤2 IU dL ?1). PK parameters were derived using observed FIX concentration levels and actual PK sampling times, and repeated in a subset of participants who had received IB1001 prophylaxis for 4–18 months. A retrospective analysis was conducted in subgroups according to the sialylation levels of IB1001 (50.8, 57.8–59.0%, or 71.7%). In the 32 adolescent and adult males evaluated, there were no clinically meaningful differences in PK parameters between those receiving IB1001 75 IU kg?1 or nonacog alfa. The lower limit of the one‐sided 95% confidence interval for the ratio of AUC0‐t and AUC0‐∞ (IB1001/nonacog alfa) was 0.90, establishing non‐inferiority. Terminal phase half‐lives were similar (29.7 ± 18.2 h for IB1001 and 33.4 ± 21.2 h for nonacog alfa). The PK results were stable for up to 18 months of IB1001 exposure; the impact of sialylation levels was not clinically meaningful. There were no clinically meaningful PK differences between IB1001 and nonacog alfa. IB1001 was well tolerated and without safety concerns. The non‐inferiority of IB1001 to nonacog alfa supports IB1001 becoming a useful alternative recombinant agent for the management of haemophilia B. 相似文献
72.
73.
74.
Jos-Ramn Blanco Ramn Morillo Vicente Abril Ismael Escobar Enrique Bernal Carlos Folguera Ftima Braas Mercedes Gimeno Olatz Ibarra Jos-Antonio Iribarren Alicia Lzaro Ana Mario Mara-Teresa Martn Esteban Martinez Luis Ortega Julian Olalla Aguas Robustillo Matilde Sanchez-Conde Miguel-Angel Rodriguez Javier de la Torre Javier Sanchez-Rubio Montse Tuset 《European journal of clinical pharmacology》2020,76(3):305-318
75.
Luis A. González Yulieth A. Upegui Luis Rivas Fernando Echeverri Gustavo Escobar Sara M. Robledo Wiston Quiñones 《Archiv der Pharmazie》2020,353(12):2000157
Chalcones are a group of natural products with many recognized biological activities, including antiparasitic activity. Although a lot of chalcones have been synthetized and assayed against parasites, the number of structural features known to be involved in this biological property is small. Thus, in the present study, 21 chalcones were synthesized to determine the effect of substituents in the A and B rings on the activity against Leishmania braziliensis, Trypanosoma cruzi, and Plasmodium falciparum. The compounds were active against L. braziliensis in a structure-dependent manner. Only one compound was very active against T. cruzi, but none of them had a significant antiplasmodial activity. The electron-donating substituents in ring B and the hydrogen bonds at C-2′ with carbonyl affect the antiparasitic activity. 相似文献
76.
77.
Gomez-Diez SG López LG Escobar ML Gutiérrez LJ Oliva NP 《Medicina oral, patología oral y cirugía bucal》2007,12(8):E602-E604
Progressive facial hemiatrophy (PFH) is a rare condition characterized by the slow, progressive appearance of a unilateral facial atrophy that affects the skin, subcutaneous tissue, muscle and bone. We report the case of a 60-year-old female patient whose cutaneous symptoms commenced in 1987 in the form of a purplish erythema on the left side of her face and neck, which subsequently remitted giving rise to an indurated region in the left maxillary region. Since 1995 until the present day, she has developed facial hemiatrophy on the left side accompanied by progressive osseous reabsorption of the upper maxilla and left mandible with atrophy of soft tissue. The association of the onset of PFH with progressive osteolysis of the maxilla has not been previously reported in an adult patient. 相似文献
78.
Bibiana Escobar Pilar Taurá Graciela Martínez-Palli Constatino Fondevila Jaume Balust Joan Beltrán Javier Fernández Juan Carlos García-Pagán Juan Carlos García-Valdecasas 《World journal of surgery》2014,38(4):927-935
Introduction
In patients with advanced cirrhosis, stressful stimuli may reveal a silent reduced cardiac performance. During liver transplantation (LT), graft reperfusion strongly stresses the heart and may unmask latent myocardial dysfunction.Aim
The objective of this study was to assess heart response to acutely increased preload after liver graft reperfusion and correlate this response with preoperative data and outcome.Methods
Preoperative clinical, echocardiographic, and hemodynamic data, and patient outcome were retrospectively recorded for 235 liver recipients who had no known cardiac disease. Myocardial dysfunction was defined as less than 10 % increase of stroke volume after graft reperfusion (non-responder).Results
We found 84 (35.7 %) non-responder patients. The non-responders showed higher Model for end-stage liver disease scores (p = 0.046), left atrial diameter (LAD) (p = 0.040), hepatic vein pressure gradient (p = 0.055), and hyperdynamic state than responders. The percentages of patients with hyponatremia (p = 0.048) and alcohol etiology (p = 0.025) were also higher among non-responders. Independent predictors of inadequate cardiac response in the multivariate analysis were low preoperative systemic vascular resistance (SVRI) [odds ratio (OR) 3.09, 95 % CI 1.15–4.82; p = 0.027] and enlargement of LAD (OR 2.08, 95 % CI 1.49–2.74; p = 0.044). Non-response was associated with higher rates of early cardiovascular events [hazard ratio (HR) 2.84, 95 % CI 1.09–4.22; p = 0.039] and higher length of intensive care unit stay (p = 0.038). No differences were found in 1-year survival rates.Conclusions
Latent cardiac dysfunction among LT recipients, considered to be abnormal stroke volume response to unclamping of portal vein, is very prevalent. SVRI and LAD were independent predictors of inadequate responses. This condition deserves special attention since it may aggravate the early postoperative course of LT. 相似文献79.
Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia 总被引:3,自引:4,他引:3
Five patients with sickle cell anemia were treated with hydroxyurea (HU), in hopes of augmenting their production of fetal hemoglobin. Laboratory responses in two patients treated for more than 2 years were encouraging and there were suggestions of clinical improvement. Long- term HU therapy should be considered for severely affected adults with sickle cell anemia who are willing to accept what is probably a small risk of carcinogenesis. Preliminary chromosomal analysis and knowledge of the clastogenic properties of HU suggest that conception and pregnancy should be avoided. Pharmacokinetic studies will probably be necessary to adjust individual dosage schedules so that cytotoxicity is avoided. F cell responses can be seen in 2 to 3 weeks if the HU dose is optimal, but establishment of a large number of F cells in the circulation may take a month or longer. 相似文献
80.
Cardoso AA; Schultze JL; Boussiotis VA; Freeman GJ; Seamon MJ; Laszlo S; Billet A; Sallan SE; Gribben JG; Nadler LM 《Blood》1996,88(1):41-48
Even if neoplastic cells express tumor associated antigens they still may fail to function as antigen presenting cells (APC) if they lack expression of one or more molecules critical for the induction of productive immunity. These cellular defects can be repaired by physiologic activation, transfection, or fusion of tumor cells with professional APC. Although such defects can be repaired, antitumor specific T cells may still fail to respond in vivo if they may have been tolerized. Here, human pre-B cell acute lymphoblastic leukemia (pre-B ALL) was used as a model to determine if primary human tumor cells can function as alloantigen presenting cells (alloAPC) or alternatively whether they induce anergy. In the present report, we show that pre-B cell ALL express alloantigen and adhesion molecules but uniformly lack B7-1 (CD80) and only a subset express B7-2 (CD86). Pre-B ALL cells are inefficient or ineffective alloAPC and those cases that lack expression of B7-1 and B7-2 also induce alloantigen specific T- cell unresponsiveness. Under these circumstances, T-cell unresponsiveness could be prevented by physiologic activation of tumor cells via CD40, cross-linking CD28, or signaling through the common gamma chain of the interleukin-2 receptor on T cells. Taken together, these results suggest that pre-B ALL may be incapable of inducing clinically significant T-cell-mediated antileukemia responses. This defect may be not only due to their inability to function as APC, but also due to their potential to induce tolerance. Attempts to induce clinically significant antitumor immune responses may then require not only mechanisms to repair the antigen presenting capacity of the tumor cells, but also reversal of tolerance. 相似文献